Enbezotinib |
| Katalog-Nr.GC65354 |
Enbezotinib, ein Inhibitor von RET, kann die RET-Autophosphorylierung hemmen. Enbezotinib kann zur Krebsforschung eingesetzt werden.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2359649-81-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer[1].
Enbezotinib (compound 5) (0.3-300 nM) inhibits p-RET (y905) in RET-driven cells[1].
Enbezotinib (compound 5) (2-5 mg/kg; twice daily for 27 days) decreases tumor size in mice[1].
[1]. ROGERS EW, et, al. Macrocyclic compounds for treating disease. WO2019126121A1.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *